MX2018013581A - Receptores de células t que reconocen mutantes de despazamiento del marco lectura de tgfbrii. - Google Patents
Receptores de células t que reconocen mutantes de despazamiento del marco lectura de tgfbrii.Info
- Publication number
- MX2018013581A MX2018013581A MX2018013581A MX2018013581A MX2018013581A MX 2018013581 A MX2018013581 A MX 2018013581A MX 2018013581 A MX2018013581 A MX 2018013581A MX 2018013581 A MX2018013581 A MX 2018013581A MX 2018013581 A MX2018013581 A MX 2018013581A
- Authority
- MX
- Mexico
- Prior art keywords
- chain domain
- recognise
- seq
- sequences
- tcr
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 3
- 230000037433 frameshift Effects 0.000 title abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 230000009258 tissue cross reactivity Effects 0.000 abstract 6
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000012642 immune effector Substances 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 abstract 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 231100000221 frame shift mutation induction Toxicity 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464434—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
La presente invención se refiere a moléculas TCR que reconocen los neopeptidos producidos como resultado de la mutación de desplazamiento del marco de lectura "1A" asociada al cáncer en TGFßRII humano. Las moléculas TCR son capaces de unirse a un péptido de SEQ ID NO: 1 cuando dicho péptido esta presentado por un MHC Clase I, y comprenden un dominio de cadena a y un dominio de cadena ß, cada dominio de cadena comprende tres secuencias de CDR, en donde a) las CDR 1, 2 y 3 del dominio de cadena a tienen las secuencias de las SEQ ID NO: 2, 3 y 4 respectivamente; y b) las CDR 1, 2 y 3 del dominio de cadena ß tienen las secuencias de las SEQ ID NO: 5, 6 y 7 respectivamente, y en donde una o mas de dichas secuencias CDR pueden opcionalmente modificarse por sustitución, adición o eliminación de 1 o 2 aminoácidos. Se proporcionan moléculas de acido nucleico que codifican dichos TCR, al igual que moléculas TCR solubles con estas secuencias de CDR. Las moléculas de acido nucleico de la invención se pueden usar para modificar las células efectoras inmunes para expresar un TCR como se define aquí, y tales células efectoras inmunes modificadas son útiles en la terapia para el cáncer, como son los TCR solubles como se definió anteriormente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608052.5A GB201608052D0 (en) | 2016-05-09 | 2016-05-09 | T-cell receptors which recognise frameshift mutants of TGF-beta RII |
| PCT/EP2017/061087 WO2017194555A1 (en) | 2016-05-09 | 2017-05-09 | T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018013581A true MX2018013581A (es) | 2019-07-04 |
Family
ID=56297359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013581A MX2018013581A (es) | 2016-05-09 | 2017-05-09 | Receptores de células t que reconocen mutantes de despazamiento del marco lectura de tgfbrii. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190336529A1 (es) |
| EP (1) | EP3455249B1 (es) |
| JP (1) | JP2019517790A (es) |
| KR (1) | KR20190016507A (es) |
| CN (1) | CN109328196B (es) |
| AU (1) | AU2017261684A1 (es) |
| CA (1) | CA3024555A1 (es) |
| EA (1) | EA201892217A1 (es) |
| GB (1) | GB201608052D0 (es) |
| IL (1) | IL262873A (es) |
| MX (1) | MX2018013581A (es) |
| SG (1) | SG11201809716VA (es) |
| WO (1) | WO2017194555A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10724043B2 (en) * | 2016-10-06 | 2020-07-28 | Nantbio, Inc. | Multi-pulse transfection methods and cells |
| WO2018104473A1 (en) | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| GB201713078D0 (en) * | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
| WO2019069125A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
| CN110938136B (zh) * | 2018-09-21 | 2022-09-09 | 香雪生命科学技术（广东）有限公司 | 一种识别afp抗原的高亲和力t细胞受体 |
| WO2020201527A1 (en) * | 2019-04-04 | 2020-10-08 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
| GB201907663D0 (en) | 2019-05-30 | 2019-07-17 | Ab Mavatar | Method for diagnosing colorectal cancer |
| WO2023050063A1 (zh) * | 2021-09-28 | 2023-04-06 | 溧阳瑅赛生物医药有限公司 | 一种识别hla-a*02:01/e629-38的tcr及其应用 |
| WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| FR2779432A1 (fr) * | 1998-06-08 | 1999-12-03 | Transgene Sa | Sequence nucleique du recepteur rii du tgfb, peptide code, et utilisations |
| BR112012001977A2 (pt) * | 2009-07-29 | 2017-01-31 | Glaxo Group Ltd | domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, proteína de fusão, ácido nucleico isolado, molécula de ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um polipeptídeo e para tratar e/ou prevenir uma condição, composição farmacêutica, uso de um domínio variável único, e, dispositivo de dispensação pulmonar. |
| ES2894398T3 (es) * | 2011-06-03 | 2022-02-14 | Xoma Technology Ltd | Anticuerpos específicos para TGF-beta |
| JP6548579B2 (ja) * | 2012-12-06 | 2019-07-24 | ヴィクトリア リンク リミテッド | コンジュゲート化合物 |
| WO2015169853A1 (en) * | 2014-05-06 | 2015-11-12 | Universitetet I Oslo | Engineered invariant chain molecule for improved mhc class i loading |
| WO2015189267A2 (en) * | 2014-06-10 | 2015-12-17 | Universitetet I Oslo | Engineered invariant chain molecule for improved mhc class i loading |
-
2016
- 2016-05-09 GB GBGB1608052.5A patent/GB201608052D0/en not_active Ceased
-
2017
- 2017-05-09 AU AU2017261684A patent/AU2017261684A1/en not_active Abandoned
- 2017-05-09 EP EP17725537.9A patent/EP3455249B1/en active Active
- 2017-05-09 JP JP2018559282A patent/JP2019517790A/ja active Pending
- 2017-05-09 WO PCT/EP2017/061087 patent/WO2017194555A1/en active Application Filing
- 2017-05-09 CA CA3024555A patent/CA3024555A1/en active Pending
- 2017-05-09 MX MX2018013581A patent/MX2018013581A/es unknown
- 2017-05-09 EA EA201892217A patent/EA201892217A1/ru unknown
- 2017-05-09 KR KR1020187035676A patent/KR20190016507A/ko active IP Right Grant
- 2017-05-09 SG SG11201809716VA patent/SG11201809716VA/en unknown
- 2017-05-09 US US16/099,329 patent/US20190336529A1/en not_active Abandoned
- 2017-05-09 CN CN201780038176.8A patent/CN109328196B/zh active Active
-
2018
- 2018-11-07 IL IL262873A patent/IL262873A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017261684A1 (en) | 2018-12-13 |
| GB201608052D0 (en) | 2016-06-22 |
| EP3455249A1 (en) | 2019-03-20 |
| SG11201809716VA (en) | 2018-11-29 |
| US20190336529A1 (en) | 2019-11-07 |
| KR20190016507A (ko) | 2019-02-18 |
| CN109328196A (zh) | 2019-02-12 |
| WO2017194555A1 (en) | 2017-11-16 |
| CN109328196B (zh) | 2022-11-01 |
| JP2019517790A (ja) | 2019-06-27 |
| EP3455249B1 (en) | 2023-05-03 |
| EA201892217A1 (ru) | 2019-08-30 |
| CA3024555A1 (en) | 2017-11-16 |
| IL262873A (en) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013581A (es) | Receptores de células t que reconocen mutantes de despazamiento del marco lectura de tgfbrii. | |
| PE20190335A1 (es) | Receptores de celulas t | |
| IL292094B2 (en) | Neoantigens and methods for using them | |
| CY1122627T1 (el) | Αντισωματα εναντι της ceacam6 και χρησεις αυτων | |
| PH12018502118A1 (en) | Chimeric receptors to flt3 and methods of use thereof | |
| EP3712165A3 (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| EP4282969A3 (en) | Compositions and methods for treating cancer with duocars | |
| WO2018172533A3 (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
| PH12017501347B1 (en) | Agonistic icos binding proteins | |
| MX2018011225A (es) | Celulas t transfectadas y receptores de celulas t de utilidad en inmunoterapias contra el cancer. | |
| MX2018011223A (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer. | |
| NZ592261A (en) | Novel immunotherapy against neuronal and brain tumors | |
| MX2017002205A (es) | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. | |
| EA201270135A1 (ru) | T-клеточные рецепторы | |
| PH12018501933A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| MX2016001837A (es) | Receptores de celulas t. | |
| MX2019006411A (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos. | |
| JP2019517790A5 (es) | ||
| MX2009009589A (es) | Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos. | |
| DK1765860T3 (da) | Ny-ESO-T.cellereceptor med höj affinitet | |
| EP4269562A3 (en) | Antigen binding molecules and methods of use thereof | |
| PH12018501892A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| NZ609916A (en) | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof | |
| MX2021012004A (es) | Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas. | |
| MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. |